Pharma in Focus
Email Address Sign-Up

Australia's most trusted source of pharma news

How to access Pharma in Focus articles
  • If you're a current subscriber, See below

  • If you're new to Pharma in Focus, Click here

  • If you haven't SUBSCRIBED yet, Click here

Current Subscribers

If you are are current Full Text Subscriber or have taken out a Free Trial, please type your email address into the form below.

This will restore your access and return you to the Home Page.

Email Address
Pipeline Monitor
BMS next up in hep C
BMS' wins key hep C approval in Europe; Sanofi's Genzyme unit given go ahead for oral Gaucher therapy; GSK adds to respiratory portfolio.
Special Report
PBAC November agenda
Our presentation of the PBAC November agenda has been divided into major and minor submissions and sorted by indication.
Working Life
Pharma, a career for life?
According to a recent survey, 70 per cent of pharma executives would like to remain in the industry throughout their working lives.
Approvals Action
Apotex and Generic Partners get busy
Apotex has been busy on the drugs register, preparing to compete in PBS markets worth close to $40 million, while Generic Partners is looking to compete with Pfizer.
PBS Snapshot
Full outcomes of July PBAC
The July PBAC meeting had an extensive agenda that included first-time submissions on major new drugs as well as some key re-submissions. Read all the results here.